TrialBlood2019

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.

Jennifer M O'Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.